KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is Tang Capital Management LLC's 8th Largest Position

Tang Capital Management LLC raised its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 13.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,893,847 shares of the specialty pharmaceutical company's stock after buying an additional 572,300 shares during the quarter. KalVista Pharmaceuticals comprises about 2.7% of Tang Capital Management LLC's holdings, making the stock its 8th largest position. Tang Capital Management LLC owned approximately 9.90% of KalVista Pharmaceuticals worth $41,451,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. SG Americas Securities LLC raised its holdings in KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after purchasing an additional 1,319 shares during the last quarter. Legal & General Group Plc boosted its position in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after acquiring an additional 1,494 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock worth $262,000 after purchasing an additional 1,670 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after buying an additional 2,043 shares during the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of KalVista Pharmaceuticals by 17.1% during the 4th quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after buying an additional 2,588 shares during the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now owns 287,811 shares of the company's stock, valued at $3,445,097.67. The trade was a 2.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were bought at an average price of $9.42 per share, with a total value of $235,500.00. Following the transaction, the insider now directly owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. The trade was a 0.47% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 15,647 shares of company stock valued at $181,770. Company insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Trading Down 3.0%

KALV traded down $0.37 on Wednesday, reaching $11.87. The company had a trading volume of 526,642 shares, compared to its average volume of 421,605. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $15.50. The company has a market capitalization of $590.13 million, a P/E ratio of -3.26 and a beta of 0.05. The company has a fifty day moving average of $12.01 and a 200-day moving average of $10.44.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 price objective on the stock. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Jones Trading restated a "buy" rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).